The abstract is read at the publisher; the summary is JClub's.
DCA-conjugated, fully chemically stabilized PARP1-selective siRNAs achieved up to 80% PARP1 mRNA knockdown in mouse liver, heart, and skeletal muscle after subcutaneous dosing.
- Why it matters: PARP1 is a key therapeutic target, but PARP inhibitors face off-target toxicity and resistance, creating a need for selective gene-silencing alternatives.
- What they did: The team screened 24 PARP1 siRNA duplexes in human and mouse cell lines, then tested lead candidates for PARP1 selectivity, mRNA/protein knockdown, and in vivo activity using DCA-conjugated siRNAs.
- The result: Lead siRNAs showed strong PARP1 knockdown with high PARP1 over PARP2 selectivity and PARP1-dependent cellular activity, supporting further evaluation for oncology and other PARP1-associated diseases.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.